BeOne Medicines, shared on LinkedIn:
“News for Investors and Media: At ESMO26, we’re presenting a late breaking abstract from our Phase 3 trial evaluating our foundational PD-1 inhibitor in combination with a dual HER2-targeted bispecific antibody plus chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
The data provide further evidence to establish this combination as the standard of care in the treatment of this condition, with survival data at three years.
You can also read: RAMIRIS Trial at ESMO 2026: FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab in Advanced Gastroesophageal Adenocarcinoma
